Cutaneous Lymphomas: New Therapies in Development

Modern therapies for cutaneous lymphomas were a topic of discussion at the European Academy of Dermatology and Venereology 2017 Congress, which was held in Geneva in September 2017.

Dr Emmanuella Guenova reviewed a number of new molecules in development, including:

  • IPH4102

This is a CD158K/KIR3DL2 inhibitor. It is a diagnostic and prognostic factor in cutaneous T cell lymphoma, and phase 1 trials have been completed showing some responses.

  • Mogamulizumab

This is a CCR4 inhibitor and phase 2 trials have been completed. In published results from phases 1 and 2 trials, an overall response rate of 37 percent was found. The molecule is already approved in Japan for adult T cell leukaemia/lymphoma.

  • Brentuximab

This is an anti-CD30 antibody. A phase 3 trial has been published with a 56.3 percent response rate. However, peripheral neuropathy was seen in 67 percent of patients and it was not always reversible.

Read more about new skin cancer therapies.

 

Source:
Guenova, E. (September 2017.) Modern therapies for cutaneous lymphomas. 26th EADV Congress 2017 Conference Review. Research Review. Page 4.


Learn more about skin cancer medicine in primary care at the next Skin Cancer Certificate Courses:

Skin Cancer Certificate Courses in Australia

Leave a Reply

Your email address will not be published. Required fields are marked *